ArticleJournal of thoracic disease2025
Clinical and dosimetric risk factors for radiation pneumonitis after proton therapy in lung cancer patients: a retrospective study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut-lung axis in radiation-induced lung injury: mechanisms and interventions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given proton therapy's potential to reduce lung dose compared to conventional radiation therapies, this retrospective study aims to identify clinical and dosimetric risk factors associated with the development of radiation pneumonitis (RP) in lung cancer patients treated at our center. Methods: A retrospective cohort analysis was conducted on lung cancer patients who received proton therapy at the Ion Medicine Center of the First Affiliated Hospital of University of Science and Technology of China from March 2022 to January 2025. Clinical characteristics and dosimetric parameters were collected and analyzed. Univariate and multivariable logistic regression analyses were performed to identify factors associated with the development of grade ≥2 RP. Results: The study included 47 lung cancer patients (30 males, 17 females) with a median age of 67 years (range: 42-88 years) and prescribed doses of 40-80 Gy [relative biological effectiveness (RBE)]. During a median follow-up of 12.0 months, 5 patients (10.6%) developed grade 2 RP; no grade 3 or higher events were observed. Univariate and multivariable analyses identified V10, V20, V30, V40, V50, V60 and mean lung dose (MLD) of the ipsilateral lung, as well as V40, V50, and V60 of the total lung, as independent risk factors for RP [adjusted odds ratio (AOR) >1, P<0.05]. Conclusions: Dosimetric parameters, specifically V10, V20, V30, V40, V50, V60, and MLD of the ipsilateral lung, along with V40, V50, and V60 of the total lung, are associated with grade ≥2 RP in lung cancer patients receiving proton radiotherapy. By identifying the risk factors associated with RP, clinicians can more effectively optimize treatment regimens, mitigate adverse effects in patients, and enhance overall treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.